ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase ...
Arrowhead Pharmaceuticals, Inc. today announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct ...
T.D. Thornton offers his final order of preference of this season's three-year-olds slated for this weekend's Kentucky Derby ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the events in which it is scheduled to participate throughout the month of May, 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results